drugset / Trial / NCT00320073
Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase 1
Completed
41 enrolled
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as vinflunine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib and pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vinflunine together with erlotinib or pemetrexed may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vinflunine when given together with erlotinib or pemetrexed in treating patients with unresectable or metastatic solid tumors.
Timeline
- Start
- 2006-08
- Primary completion
- 2008-10
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 75 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Pemetrexed | Small molecule | — | Intravenous |
| Subject | Vinflunine | Small molecule | — | Intravenous |